Affimed to Present at Upcoming Investor Conferences
01. September 2022 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress
11. August 2022 06:30 ET
|
Affimed N.V.
AFM13 monotherapy: On track to report topline data of the registration-directed REDIRECT trial in the fourth quarter of 2022AFM13 combination with natural killer (NK) cells: On track to report updated...
Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022
04. August 2022 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Establishes Scientific Advisory Board
30. Juni 2022 16:00 ET
|
Affimed N.V.
Independent advisory panel to be made up of distinguished, key opinion leaders with scientific and clinical expertise in innate immunity and oncologyScientific Advisory Board to provide guidance on...
Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
10. Juni 2022 10:31 ET
|
Affimed N.V.
AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational statusStudy demonstrated specific anti-tumor response even at low levels of...
Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress
01. Juni 2022 06:30 ET
|
Affimed N.V.
AFM13 monotherapy: Completed enrollment in the REDIRECT study for patients with relapsed or refractory PTCL; on track to report topline data in the fourth quarter of 2022AFM13 combination with NK...
Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
26. Mai 2022 17:05 ET
|
Affimed N.V.
Design and rationale of the phase 1/2a open label, multicenter study of the AFM24 monotherapy in patients with advanced EGFR-expressing solid tumorsDesign and rationale of the phase 1/2a study of...
Affimed to Present at the 2022 Jefferies Healthcare Conference
26. Mai 2022 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, May 26, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022
24. Mai 2022 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, May 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Announces Annual General Meeting of Shareholders
24. Mai 2022 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, May 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...